Microbiologist and virologist, Dr Gagandeep Kang speaks with Kiran Mazumdar-Shaw, the founder-chairperson of one of India’s largest pharmaceutical companies, about India’s flawed vaccine roll-out, and the trade-offs between patents and pricing.  Highlights India’s vaccine roll-out programme: How does one decide who gets priority and who does not? What does the Indian government need to do to ensure vaccines are affordable and available for everyone? What role should the private sector play in India’s vaccine roll-out programme? Should COVID-19 vaccines be protected by patents?  For more information about IDR, go to www.idronline.com. Also, follow IDR on Facebook, Linkedin, Twitter and Instagram. Read more India’s COVID-19 vaccine drive is excluding millions of citizens India’s COVID-19 response limited by strong urban and tech bias Fighting the pandemic: Two contrasting approaches[T1] How rebuilding trust in the public healthcare system can help combat vaccine hesitancy in rural communities A ‘corona demon’ raises awareness about COVID-19 in rural Andhra Pradesh A pathway to universal healthcare in India Engaging communities is critical to the COVID-19 response Is the COVID-19 vaccine in India a public or a private good? Upholding trust in vaccination Covid-19 Pandemic: Shortages, Hesitancy and Pricing Plague India’s Covid-19 Vaccination Programme All work, no vaccines: Security guards and COVID-19 Learn more about the Coalition for Epidemic Preparedness Innovations or Cepi ‘None are safe until all are safe’: COVID-19 vaccine rollout in low- and middle-income countries Covid: The vaccine patent row explained This podcast is a Maed in India production, you can find out more about us https://www.maedinindia.in/